Time to put an end to the "one size fits all" approach to bisphosphonate use in patients with metastatic breast cancer?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it.

1. Is De-escalated Bisphosphonates Therapy a Suitable Alternative to Standard Dosing in Malignant Tumor Patients With Bone Metastases: A Systematic Review and Meta-Analysis.Frontiers in oncology · 2019
   Pooled it
2. A phase II, multicentre trial evaluating the efficacy of de-escalated bisphosphonate therapy in metastatic breast cancer patients at low-risk of skeletal-related events.Breast cancer research and treatment · 2014
   Trial
3. Cancer treatment comes to age: from one-size-fits-all to next-generation sequencing (NGS) technologies.BioImpacts : BI · 2024
   Review
4. Histomorphometric and microarchitectural analysis of bone in metastatic breast cancer patients.Bone reports · 2021
   Article
5. Efficacy and safety of de-escalation bone- modifying agents for cancer patients with bone metastases: a systematic review and meta-analysis.Cancer management and research · 2018
   Article
6. A phase 2 trial exploring the clinical and correlative effects of combining doxycycline with bone-targeted therapy in patients with metastatic breast cancer.Journal of bone oncology · 2016
   Article
7. Future directions for bone metastasis research - highlights from the 2015 bone and the Oncologist new updates conference (BONUS).Journal of bone oncology · 2016
   Review
8. Systemic treatment approaches in her2-negative advanced breast cancer-guidance on the guidelines.Current oncology (Toronto, Ont.) · 2015
   Review
9. Publishing clinical research: ten pearls for oncology trainees and junior oncologists.Current oncology (Toronto, Ont.) · 2015
   Article
10. Bone-targeted therapy for metastatic breast cancer-Where do we go from here? A commentary from the BONUS 8 meeting.Journal of bone oncology · 2014
    Article
11. Incidence, consequences and treatment of bone metastases in breast cancer patients-Experience from a single cancer centre.Journal of bone oncology · 2013
    Article
12. A systematic review of dosing frequency with bone-targeted agents for patients with bone metastases from breast cancer.Journal of bone oncology · 2013
    Review
13. Bone-targeted agent use for bone metastases from breast cancer and prostate cancer: A patient survey.Journal of bone oncology · 2013
    Article
14. Bone-Targeted Agents for the Management of Breast Cancer Patients with Bone Metastases.Journal of clinical medicine · 2013
    Review
15. De-escalated administration of bone-targeted agents in patients with breast and prostate cancer-A survey of Canadian oncologists.Journal of bone oncology · 2013
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

3 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.